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Background: Erythrocyte invasion by Plasmodium falciparum
parasites is central to malaria pathogenesis. Thus, it is critical to
understand this intricate biological process for the development
of novel malaria intervention strategies. P. falciparum erythrocyte
invasion is a complex,multistep process that ismediated by a num-
ber of redundant ligand-receptor interactions. Extensive research
over three decades has aimed at identifying an essential parasite
ligand that could be targeted across multiple parasite strains. In
this regard, PfRH5 was identiﬁed as a critical ligand that binds with
the erythrocyte receptor, Basigin and elicits potent cross-strain
neutralizing antibodies. We have for the ﬁrst time expressed full-
length recombinant PfRH5 in E. coli with a structural integrity that
mimics the native parasite protein. Our recombinant PfRH5 pro-
tein is functional, binds with Basigin and elicits potent cross-strain
transcending parasite neutralising antibodies that substantiates
its claim as a leading vaccine candidate (IAI, 2014). In addition,
PfRH5 lacks a transmembrane domain or GPI anchor and thus
a major question has been that how PfRH5 is anchored on the
merozoite surface during invasion such that it can engage with
its receptor Basigin and mediate attachment. We have successfully
solved this conundrumand identiﬁedanessential, novel, conserved
GPI-anchored parasite molecule, CyRPA that tethers PfRH5 on the
parasite surface as a multiprotein complex (PNAS 2015).
Methods & Materials: We have produced different fragments
of PfRH5/CyRPA recombinant proteins, functionally characterized
their binding properties and measured the parasite neutralizing
ability of their antibodies.
Results: We demonstrate that PfRH5/CyRPA monoclonal and
polyclonal antibodies potently block erythrocyte invasion syner-
gistically in a strain-transcending manner by abrogating formation
of the PfRH5/CyRPA essential complex. We have thus identiﬁed a
new conserved mechanism overcoming the previous challenges of
blood-stage vaccines (antigen diversity, redundancy, heterologous
strain cross-reactivity) paving the way forward to develop new
generation blood stage P. falciparum vaccines based on PfRH5 and
CyRPA.
Conclusion: Our previous discovery had elucidated the for-
mation of a novel multi-protein PfRH5/CyRPA complex essential
for erythrocyte invasionl, which we have validated in vitro as a
new potent target for the development of novel blood-stage vac-
cines that could elicit protection alone or in combination with the
advanced pre-erythrocytic RTS.S sub-unit vaccine.
http://dx.doi.org/10.1016/j.ijid.2016.02.893
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Background: Enteric and diarrheal diseases are important
causes of childhood death in the developing world. These diseases
are responsible for more than 750 thousand deaths in children
under 5 years old, ranking second cause of death, after lower res-
piratory diseases, in this age group . Among the major causative
agents of diarrhea is Escherichia coli (E. coli). There are several vac-
cine trials for diarrheagenic E. coli. However, diarrheagenic E. coli
has many categories and pathotypes and vaccines are directed
for one or two of the ﬁve main pathotypes-causing diarrhea. Cur-
rently, there are no combined vaccines available in the market for
all ﬁve diarrheagenic E. coli categories and pathotypes. Therefore,
we aimed to develop a low-cost vaccine candidate combining the
ﬁve main diarrheagenic E.coli to offer wide-spectrum protection.
We formulated a formalin-killed whole-cell mixture of enteroag-
gregative, enteropathogenic, enteroinvasive, enterohemorrhagic,
and enterotoxigenic E. coli strains as a combined vaccine candidate
Methods & Materials: We immunized Balb/C mice subcuta-
neously with 10(9) CFU of combined vaccine candidate to evaluate
survival rate, and we immunized mice groups with combined vac-
cine candidate and monitored biomarkers levels over six weeks as
well as measuredresponses post challenge with relevant live E. coli
Results:We found a signiﬁcant increase in survival percent post
challenged compared to unimmunized controls (p < 0.0001, 100%
survival). We found also signiﬁcant increase in speciﬁc systemic
antibodies (IgG), interferon gamma (IFN) and interleukin 6 (IL-6)
levels elicited by combined vaccine candidate especially in the ﬁrst
twoweeks aftermice immunization compared to controls (p<0.05).
We found also that CTB-adjuvantedcombined vaccine candidate
showed higher IgG and IFN levels than alum (p<0.05).
Conclusion: Overall, our combined vaccine candidate offered
protection from the ﬁve main diarrheagenic E. coli pathotypes in
a single vaccine using mouse model. To the best of our knowl-
edge, this is the ﬁrst combined vaccine against the ﬁve main
diarrheagenic E. coli pathotypes that is cost-effective with promise
for further testing in humans.
http://dx.doi.org/10.1016/j.ijid.2016.02.894
